Boothbay Fund Management’s Cymabay Therapeutics CBAY Stock Holding History

Boothbay Fund Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21,582	Closed	-$322K	–	2092
2023 Q3	$322K	Buy	+21,582	New	+$286K	0.01%	1221
2023 Q2	–	Sell	-16,249	Closed	-$142K	–	2467
2023 Q1	$142K	Sell	16,249 -1,822	-10%	-$14.6K	﹤0.01%	1839
2022 Q4	$113K	Buy	+18,071	New	+$68.7K	﹤0.01%	1753
2022 Q3	–	Sell	-14,479	Closed	-$43K	–	2711
2022 Q2	$43K	Buy	+14,479	New	+$34.6K	﹤0.01%	2087
2020 Q3	–	Sell	-159,465	Closed	-$557K	–	1277
2020 Q2	$557K	Sell	159,465 -54,971	-26%	-$159K	0.04%	549
2020 Q1	$317K	Buy	+214,436	New	+$360K	0.03%	558
2019 Q4	–	Sell	-26,790	Closed	-$137K	–	1038
2019 Q3	$137K	Buy	+26,790	New	+$162K	0.01%	684
2017 Q4	–	Sell	-50,077	Closed	-$404K	–	840
2017 Q3	$404K	Buy	+50,077	New	+$339K	0.07%	306
2015 Q4	–	Sell	-21,897	Closed	-$42K	–	684
2015 Q3	$42K	Buy	+21,897	New	+$59.6K	0.02%	431

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boothbay Fund Management's CBAY Position: Q4 2023 in Review

Boothbay Fund Management sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 21,582 shares — an estimated $322K sold.

Boothbay Fund Management first reported a position in CBAY in Q3 2015 and held it in 9 quarters. The position peaked at $557K in Q2 2020. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

Boothbay Fund Management reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
Boothbay Fund Management sold 21,582 Cymabay Therapeutics shares in Q4 2023, an estimated $322K.
Boothbay Fund Management first reported a position in Cymabay Therapeutics in Q3 2015 and held it in 9 quarters.
Boothbay Fund Management's Cymabay Therapeutics position peaked at $557K in Q2 2020.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Boothbay Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.